BC Innovations | Jun 20, 2019
Translation in Brief

Turning Tregs against cancer

Researchers from Massachusetts General Hospital found that inhibiting a signalosome complex in Treg cells could convert the immunosuppressive cell type into inflammatory cells in tumors, a strategy that could both increase the efficacy of checkpoint...
BC Innovations | Jun 11, 2019
Distillery Therapeutics

Inhibiting BCL10 or MALT1 for melanoma

DISEASE CATEGORY: Cancer INDICATION: Melanoma Mouse studies suggest inhibiting BCL10 or MALT1 could help treat melanoma. In a syngeneic mouse model of melanoma, Treg-specific knockout of BCL10 decreased tumor size compared with normal BCL10 expression....
BC Innovations | Jun 11, 2019
Distillery Therapeutics

CARD11, MALT1 inhibition sensitizes melanoma, colorectal tumors to PD-1 inhibitors

DISEASE CATEGORY: Cancer INDICATION: Melanoma; colorectal cancer Mouse studies suggest inhibiting CARD11 or MALT1 could help sensitize melanoma and colorectal cancer to PD-1 inhibitors. In mouse models of melanoma and colon cancer, conditional knockout of...
BC Innovations | Mar 1, 2019
Translation in Brief

Targeting pathogenic Th17 cells

A recent pair of studies offers two new approaches to treating autoimmune diseases that go after the source of Th17-mediated inflammation. T helper type 17 (Th17) cells are effector T cells that secrete the cytokine...
BC Innovations | Feb 12, 2019
Translation in Brief

Stabilizing mutant proteins

A team from Novartis Institutes for BioMedical Research (NIBR) and University of British Columbia has hit upon a strategy for treating diseases caused by loss-of-function protein mutations: target allosteric pockets on the mutant proteins to...
BC Innovations | Feb 5, 2019
Distillery Therapeutics

Hematology

INDICATION: Immunodeficiency Cell culture studies identified two allosteric stabilizers of mutant MALT1 that could help treat combined immunodeficiency in patients harboring the loss-of-function W580S mutation of MALT1, which results in low B cell counts. In...
BC Week In Review | Jan 4, 2019
Company News

AbbVie gets rights to Lupin's MALT1 program

Lupin Ltd. (NSE:LUPIN; BSE:500257) granted AbbVie Inc. (NYSE:ABBV) exclusive, worldwide rights to a portfolio of mucosa-associated lymphoid tissue lymphoma translocation gene 1 (MALT1) inhibitors, which the U.S. pharma intends to develop for hematological cancers. AbbVie...
BC Extra | Dec 25, 2018
Company News

AbbVie gets rights to Lupin's MALT1 program

Lupin Ltd. (NSE:LUPIN; BSE:500257) granted AbbVie Inc. (NYSE:ABBV) exclusive, worldwide rights to a portfolio of mucosa-associated lymphoid tissue lymphoma translocation gene 1 (MALT1) inhibitors, which the U.S. pharma intends to develop for hematological cancers. AbbVie...
BC Innovations | Oct 22, 2015
Translation in Brief

Unique ubiquity

A University of Lausanne team has turned to the U.K.'s MRC Technology for help in developing a therapeutic from the team's 2013 finding that monoubiquitination can activate the protease MALT1 in diffuse large B cell...
BC Week In Review | Oct 19, 2015
Company News

MRC Technology, University of Lausanne deal

MRC Technology and the university partnered to develop small molecules inhibitors of mucosa associated lymphoid tissue lymphoma translocation protein 1 ( MALT1 ) to treat diffuse large B cell lymphoma. The immunomodulatory enzyme is required to trigger...
Items per page:
1 - 10 of 19